Page 82 - Schwartz Principios de Cirugía, Capítulo 33 Páncreas

304. Lillemoe K, Cameron JL, Kaufman HS, Yeo CJ, Pitt HA, Sauter 324. Moon HJ, Heo JS, Choi SH, et al. The efficacy of the prophylactic 1421
PK. Chemical splanchnicectomy in patients with unresectable use of octreotide after a pancreaticoduodenectomy. Yonsei Med J.
pancreatic cancer. A prospective randomised trial. Ann Surg. 2005;46:788-793.
1993;217: 447-455. 325. Srivastava S, Sikora SS, Pandey CM, et al. Determinants of pan-
305. Singh SM, Reber HA. Surgical palliation for pancreatic cancer. creaticoenteric anastomotic leak following pancreaticoduodenec-
Surg Clin North Am. 1989;69:599-611. tomy. ANZ J Surg. 2001;71:511-515.
306. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gem- 326. Suc B, Msika S, Piccinini M, et al. Octreotide in the preven-
citabine (2,2’-difluorodeoxycytidine) in patients with adenocar- tion of intra-abdominal complications following elective
cinoma of the pancreas. Invest New Drugs. 1994;12:29-34. pancreatic resection: a prospective, multicenter randomized
307. Conroy T, Desseigne F, Ychou M, et al. Folfirinox versus gem- controlled trial. Arch Surg. 2004;139:288-294, discussion
citabine for metastatic pancreatic cancer. N Engl J Med. 2011; 295.
364: 1817-1825. 327. Aranha GV, Hodul PJ, Creech S, Jacobs W. Zero mortality after
308. Martin RC II, McFarland K, Ellis S, Velanovich V. Irrevers- 152 consecutive pancreaticoduodenectomies with pancreatico-

able electroporation therapy in the management of locally ad - gastrostomy. J Am Coll Surg. 2003;197:223-231, discussion 231- caPÍTULO 33
vanced pancreatic adenocarcinoma. J Am Coll Surg. 2012; 232.
215: 361-369. 328. Lillemoe KD, Cameron JL, Kim MP, et al. Does fibrin glue
309. Bachellier P, Nakano H, Oussoultzoglou PD, et al. Is pancreatico- sealant decrease the rate of pancreatic fistula after pancreatico-
duodenectomy with mesentericoportal venous resection safe and duodenectomy? Results of a prospective randomized trial. J Gas-
worthwhile? Am J Surg. 2001; 182: 120-129. trointest Surg. 2004;8:766-772, discussion 772-774. Páncreas
310. van Geenen RC, ten Kate FJ, de Witt LT, et al. Segmental 329. Nakao A, Fujii T, Sugimoto H, et al. Is pancreaticogastrostomy
resection and wedge excision of the portal or superior mesen- safer than pancreaticojejunostomy? J Hepatobiliary Pancreat
teric vein during pancreaticoduoodenectomy. Surgery. 2001; Surg. 2006;13:202-206.
129: 158-163. 330. Payne RF, Pain JA. Duct-to-mucosa pancreaticogastrostomy is a
311. Giulianotti PC, Sbrana F, Bianco FM, et al. Robot-assisted lapa- safe anastomosis following pancreaticoduodenectomy. Br J Surg.
roscopic pancreatic surgery: single-surgeon experience. Surg 2006;93:73-77.
Endosc. 2010; 24: 1646-1657. 331. Peng S, Mou Y, Cai X, et al. Binding pancreaticojejunostomy
312. Yamaguchi K, Kishinaka M, Nagai E, et al. Pancreatoduodenec- is a new technique to minimize leakage. Am J Surg. 2002;183:
tomy for pancreatic head carcinoma with or without pylorus pres- 283-285.
ervation. Hepatogastroenterol. 2001;48:1479-1485. 332. Rosso E, Bachellier P, Oussoultzoglou E, et al. Toward zero pan-
313. Ohtsuka T, Yamaguchi K, Ohuchida J, et al. Comparison of qual- creatic fistula after pancreaticoduodenectomy with pancreatico-
ity of life after pylorus-preserving pancreatoduodenectomy and gastrostomy. Am J Surg. 2006;191:726-732, discussion 733-734.
Whipple resection. Hepatogastroenterol. 2003; 50:846-850. 333. Sutton CD, Garcea G, White SA, et al. Isolated Roux-loop pancre-
314. Fisher WE, Hodges SE, Silbefein EJ, et al. Pancreatic resection aticojejunostomy: A series of 61 patients with zero postoperative
without routine intraperitoneal drainage. HPB (Oxford) 2011; 13: pancreaticoenteric leaks. J Gastrointest Surg. 2004;8:701-705.
503-510. 334. Suzuki Y, Kuroda Y, Morita A, et al. Fibrin glue sealing for the
315. Sindelar WF, Kinsella TJ. Studies of intraoperative radiotherapy in prevention of pancreatic fistulas following distal pancreatectomy.
carcinoma of the pancreas. Ann Oncol. 1999;10:226-230. Arch Surg. 1995;130:952-955.
316. Birkmeyer JD, Finlayson SR, Tosteson AN, et al. Effect of 335. Yeo CJ, Cameron JL, Maher MM, et al. A prospective ran-
hospital volume on in-hospital mortality with pancreaticoduo- domized trial of pancreaticogastrostomy versus pancreati-
denectomy. Surgery. 1999;125:250. cojejunostomy after pancreaticoduodenectomy. Ann Surg.
317. Gordon TA, Bowman HM, Tielsch JM, et al. Statewide regional- 1995;222:580, discussion 588.
ization of pancreaticoduodenectomy and its effect on in-hospital 336. Wente MN, Shrikhande SV, Muller MW, et al. Pancreaticoje-
mortality. Ann Surg. 1998;228:71-78. junostomy vs. pancreaticogastrostomy: Systematic review and
318. Buchler M, Friess H, Klempa I, et al. Role of octreotide in the meta-analysis. Am J Surg. 2007;193:171-183.
prevention of postoperative complications following pan- 337. Suzuki Y, Fujino Y, Tanioka Y, et al. Selection of pancreatico-
creatic resection. Am J Surg. 1992;163:125-130, discussion jejunostomy techniques according to pancreatic texture and duct
130-131. size. Arch Surg. 2002;137:1044-1047, discussion 1048.
319. Montorsi M, Zago M, Mosca F, et al. Efficacy of octreotide in the 338. Reid-Lombardo KM, Farnell MB, Crippa S, et al. Pancreatic
prevention of pancreatic fistula after elective pancreatic resections: anastomotic leakage after pancreaticoduodenectomy in 1,507
A prospective, controlled, randomized clinical trial. Surgery. patients: a report from the Pancreatic Anastomotic Leak Study
117:26-31. Group. J Gastrointest Surg. 2007;11:1451-1458.
320. Pederzoli P, Bassi C, Falconi M, et al. Efficacy of octreotide in 339. Poon RT, Lo SH, Fong D, et al. Prevention of pancreatic anas-
the prevention of complications of elective pancreatic surgery. tomotic leakage after pancreaticoduodenectomy. Am J Surg.
Italian Study Group. Br J Surg. 1994;81:265-269. 2002;183:42-52.
321. Barnett SP, Hodul PJ, Creech S, et al. Octreotide does not prevent 340. Okamoto A, Tsuruta K. Fistulation method: simple and safe
postoperative pancreatic fistula or mortality following pancreati- pancreaticojejunostomy after pancreatoduodenectomy. Surgery.
coduodenectomy. Am Surg. 2004;70:222-226, discussion 227. 2000;127:433-438.
322. Hesse UJ, DeDecker C, Houtmeyers P, et al. Prospectively 341. Yang YM, Tian XD, Zhuang Y, et al. Risk factors of pancreatic
randomized trial using perioperative low-dose octreotide to leakage after pancreaticoduodenectomy. World J Gastroenterol.
prevent organ-related and general complications after pan- 2005;11:2456-2461.
creatic surgery and pancreatico-jejunostomy. World J Surg. 342. Di Carlo V, Chiesa R, Pontiroli AE, et al. Pancreatoduodenec-
29:1325-1328. tomy with occlusion of the residual stump by Neoprene injection.
323. Lowy AM, Lee JE, Pisters PW, et al. Prospective, random- World J Surg. 1989;13:105-110, discussion 110-111.
ized trial of octreotide to prevent pancreatic fistula after pan- 343. Buchler MW, Friess H, Wagner M, et al. Pancreatic fis-
creaticoduodenectomy for malignant disease. Ann Surg. 226: tula after pancreatic head resection. Br J Surg. 2000;87:
632-641. 883-889.

booksmedicos.org